Keros Therapeutics appointed Charles Newton as a Class III director to its Board, effective March 9, 2026. Mr. Newton will also serve as a member of the Compensation Committee and the Audit Committee. Dr. Carl Gordon resigned from the Board and the Compensation Committee, effective March 9, 2026, with his departure not stemming from any disagreement with the company. Mr. Newton's compensation includes an initial stock option grant and RSU grant, each with a grant date fair value of $150,000, vesting over three years, plus annual grants and cash retainers totaling $57,000 for Board and committee service. The company issued a press release on February 26, 2026, announcing these director changes.